Orphan Disease Firm Hyperion Files for Potential $57M IPO
Hyperion Therapeutics Inc. joined the initial public offering (IPO) queue Friday, filing an S-1 aiming to raise as much as $57 million to advance pivotal studies, and possible commercial launch, of lead drug Ravicti (glycerol phenylbutyrate) in two orphan indications: urea cycle disorders (UCD) and hepatic encephalopathy.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter